Jump to a section
- Reported plasma concentrations and age-related decline
- Human observational and clinical evidence
- Preclinical and mechanistic studies relevant to aging
- Evidence gaps and next research steps
- Reported study-design details from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More GHK-Cu research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide present in human plasma that forms a high‑affinity copper chelate (GHK‑Cu) and has been studied for tissue remodeling, anti‑inflammatory, and antioxidant activities in preclinical and review literature. Reported plasma concentrations show an age-associated decline in cross‑sectional observations, and several preclinical models describe mechanistic pathways potentially relevant to age‑related tissue dysfunction. However, clinical human data remain limited and heterogeneous in scope. [S3, S1]
Reported plasma concentrations and age-related decline
A cross‑sectional description in the reviewed literature reports average human serum GHK concentrations of ~200 ng/mL at age 20 and ~80 ng/mL by age 60, indicating an observed age‑related decline in circulating GHK levels. [S3]
In a small observational human comparison, plasma GHK measured by reversed‑phase HPLC was lower in a cohort of patients with COPD (n = 9) than in age‑paired healthy subjects (n = 11), reported as 70.27 ± 38.87 ng/mL versus 133.0 ± 54.54 ng/mL respectively, and these plasma values were statistically compared with muscle and inflammatory markers in that study. [S8]
Human observational and clinical evidence
The reviewed human evidence includes small observational measurements: the COPD study reported reduced plasma GHK levels and associations between those levels and pectoralis muscle area, TNF‑α, and SOD2 in that sample, but the cohort sizes were small (COPD n = 9; controls n = 11) and represent an exploratory clinical observation. [S8]
Multiple narrative reviews note a scarcity of controlled clinical trials addressing GHK or its derivatives for clinical endpoints; for example, topical GHK derivatives have few published clinical studies despite commercial use, and reviews of peptide therapies highlight limited human data supporting musculoskeletal or regenerative clinical indications. [S2] [S4] [S6]
Preclinical and mechanistic studies relevant to aging
Review and gene‑expression analyses summarized in the literature attribute broad regenerative and protective actions to GHK/GHK‑Cu, including stimulation of collagen and glycosaminoglycan synthesis, promotion of angiogenesis and nerve outgrowth, anti‑inflammatory effects, and modulation of multiple biochemical pathways that may relate to tissue repair and aging processes. [S1]
Experimental animal and cell studies in the reviewed sources demonstrate mechanistic and functional effects: liposomal GHK‑Cu formulations increased endothelial cell proliferation and angiogenesis and shortened wound healing time in a mouse scald model, while GHK‑Cu rescued cigarette smoke‑induced skeletal muscle dysfunction in mice via a SIRT1‑dependent pathway and produced dose‑dependent improvements in muscle mass, cross‑sectional area, and grip strength in that model. [S7] [S8]
Evidence gaps and next research steps
The reviewed literature repeatedly highlights gaps: limited clinical trials (topical or systemic) testing GHK/GHK‑Cu for age‑related endpoints, insufficient data on pharmacokinetics and tissue penetration for formulations used in humans, variable preclinical models, and limited safety and efficacy data in rigorous human studies. These sources emphasize the need for standardized measurement methods, larger observational cohorts, and well‑designed clinical trials to clarify the relevance of circulating GHK concentrations to aging outcomes. [S2] [S4] [S5] [S6]
Reported study-design details from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S3] | Journal Article | human serum (cross‑sectional description) | ~200 ng/mL (age 20); ~80 ng/mL (age 60) | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Reported average GHK concentrations of ~200 ng/mL at age 20 and ~80 ng/mL at age 60; GHK forms high‑affinity copper chelate (GHK‑Cu). |
| [S8] | Journal Article (observational human study) | human patients with COPD (n = 9) and age‑paired healthy subjects (n = 11) | 70.27 ± 38.87 ng/mL (COPD) vs 133.0 ± 54.54 ng/mL (healthy controls) | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Plasma GHK measured by reversed‑phase HPLC; reported associations between plasma GHK and pectoralis muscle area, TNF‑α, and SOD2. |
| [S8] | Journal Article (in vivo animal experiment) | C57BL/6 mice (cigarette smoke‑exposure muscle dysfunction model) | 0.2 mg/kg and 2 mg/kg (reported treatment groups in the study) | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | GHK‑Cu was reported to bind and activate SIRT1 and to rescue cigarette smoke‑induced muscle dysfunction; outcomes included reduced muscle mass loss, increased muscle cross‑sectional area, and improved grip strength at reported doses. |
| [S7] | Journal Article (in vitro and in vivo animal study) | mouse scald wound model and human umbilical vein endothelial cells (HUVECs) | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Liposome‑encapsulated GHK‑Cu increased HUVEC proliferation, enhanced angiogenesis markers (VEGF, FGF‑2), and shortened wound healing time to 14 days in the scald model versus free GHK‑Cu. |
Limitations and research gaps
- Human plasma concentration reports are sparse and based on small cohorts or aggregated review data; population variability and assay differences are important confounders (e.g., small COPD cohort n = 9 vs controls n = 11 in the reviewed sample).
- Many mechanistic findings are from in vitro or animal models; translation to human aging endpoints has not been established in randomized clinical trials.
- Formulation, delivery route, and pharmacokinetics in humans (including skin permeability for topical products) are inadequately characterized in the reviewed sources.
- Measured plasma values and reported associations do not establish causality between circulating GHK levels and aging phenotypes.
Documentation checklist
- Locate the original full-text sources for reported plasma concentrations before citing absolute values.
- Confirm assay method (e.g., HPLC) and sample handling when comparing plasma values across studies.
- Distinguish human observational measurements from animal dosing and mechanistic experiments.
- Do not infer clinical benefit from preclinical or small observational studies.
- Note sample sizes and population characteristics when interpreting reported group means.
Related research supplies
- laboratory sample storage boxes (documenting aliquot IDs)
- cryogenic storage labels and color‑coded inventory stickers
- refrigerated sample transport containers for plasma specimens
- barcode inventory system for sample tracking
- biosafety cabinet cleaning wipes and surface disinfectant documentation
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Batch and inventory labeling
Phomemo M110 Label and Barcode Printer
A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.
Label-printer refill
Phomemo M110 White Replacement Labels
White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.. International journal of molecular sciences. 2018. PMID: 29986520. DOI: 10.3390/ijms19071987
- [S2] Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.. BioImpacts : BI. 2025. PMID: 39963574. DOI: 10.34172/bi.30071
- [S3] Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide.. Aging pathobiology and therapeutics. 2020. PMID: 35083444. DOI: 10.31491/apt.2020.03.014
- [S4] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
- [S5] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
- [S6] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
- [S7] Wang X, Liu B, Xu Q, Sun H, Shi M, Wang D. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis.. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2017. PMID: 28370978. DOI: 10.1111/wrr.12520
- [S8] Deng M, Zhang Q, Yan L, Bian Y, Li R, Gao J. Glycyl-l-histidyl-l-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway.. Journal of cachexia, sarcopenia and muscle. 2023. PMID: 36905132. DOI: 10.1002/jcsm.13213
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.